X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (71) 71
index medicus (63) 63
hematology (56) 56
male (49) 49
chronic myeloid leukemia (45) 45
female (45) 45
oncology (42) 42
middle aged (37) 37
aged (36) 36
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (32) 32
chronic myelogenous leukemia (27) 27
imatinib (27) 27
imatinib mesylate (27) 27
adult (26) 26
antineoplastic agents - therapeutic use (24) 24
leukemia (22) 22
hemic and lymphatic diseases (21) 21
pyrimidines - therapeutic use (21) 21
therapy (21) 21
treatment outcome (21) 21
aged, 80 and over (20) 20
dasatinib (20) 20
protein kinase inhibitors - therapeutic use (18) 18
pyrimidines - administration & dosage (18) 18
tyrosine kinase inhibitors (17) 17
cml (16) 16
bcr-abl (15) 15
benzamides (15) 15
piperazines - therapeutic use (15) 15
tyrosine (15) 15
chronic myeloid-leukemia (14) 14
follow-up (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - genetics (14) 14
leukemia, myelogenous, chronic, bcr-abl positive - pathology (14) 14
follow-up studies (12) 12
recommendations (12) 12
myeloid leukemia (11) 11
pyrimidines - adverse effects (11) 11
antineoplastic agents - adverse effects (10) 10
cancer (10) 10
cml patients (10) 10
hematology, oncology and palliative medicine (10) 10
leukemia, myelogenous, chronic, bcr-abl positive - mortality (10) 10
molecular response (10) 10
nilotinib (10) 10
patients (10) 10
piperazines - administration & dosage (10) 10
adolescent (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (9) 9
protein kinase inhibitors - adverse effects (9) 9
remission induction (9) 9
young adult (9) 9
expression (8) 8
fusion proteins, bcr-abl - genetics (8) 8
management (8) 8
risk factors (8) 8
antineoplastic agents - administration & dosage (7) 7
bcr-abl1 (7) 7
breccia (7) 7
chronic-phase (7) 7
disease-free survival (7) 7
kinases (7) 7
leukemia, myeloid, chronic-phase - drug therapy (7) 7
protein kinase inhibitors - administration & dosage (7) 7
protein-tyrosine kinase (7) 7
protein-tyrosine kinases - antagonists & inhibitors (7) 7
antimitotic agents (6) 6
antineoplastic agents (6) 6
benzamides - therapeutic use (6) 6
care and treatment (6) 6
complete molecular remission (6) 6
flow cytometry (6) 6
further section (6) 6
interferon-alpha (6) 6
italy (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - epidemiology (6) 6
philadelphia-chromosome (6) 6
research (6) 6
resistance (6) 6
retrospective studies (6) 6
survival rate (6) 6
thiazoles - administration & dosage (6) 6
thiazoles - adverse effects (6) 6
thiazoles - therapeutic use (6) 6
transcription (6) 6
acute lymphoblastic-leukemia (5) 5
age (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
apoptosis (5) 5
apoptosis - drug effects (5) 5
bcr protein (5) 5
cell line, tumor (5) 5
chronic phase (5) 5
diagnosis (5) 5
imatinib mesylate - administration & dosage (5) 5
in-vitro (5) 5
medicine (5) 5
medicine & public health (5) 5
neoplasms. tumors. oncology. including cancer and carcinogens (5) 5
original (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Management Issues, ISSN 1973-4832, 10/2015, Volume 5, Issue 6S, pp. 3 - 4
Journal Article
Journal Article
Journal Article
Molecular Cancer, ISSN 1476-4598, 02/2018, Volume 17, Issue 1, pp. 56 - 15
Journal Article
American Journal of Hematology, ISSN 0361-8609, 10/2015, Volume 90, Issue 10, pp. 910 - 914
Journal Article
Leukemia, ISSN 0887-6924, 09/2019
There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2017, Volume 23, Issue 23, pp. 7189 - 7198
Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML) has generated an... 
Tyrosine | BCR protein | Imatinib | Transformation | Myeloid leukemia | Leukemia | Chronic myeloid leukemia | Kinases | Patients | Intolerance | Experimental design | Diagnosis | Protein-tyrosine kinase | Cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2014, Volume 9, Issue 7, p. e101848
Journal Article
BMC Cancer, ISSN 1471-2407, 02/2013, Volume 13, Issue 1, p. 60
Journal Article
Journal Article
ANTICANCER RESEARCH, ISSN 0250-7005, 07/2019, Volume 39, Issue 7, pp. 3949 - 3954
We report the case of an 89-year-old male diagnosed with chronic-phase CML and expressing a rare e13a3 BCR-ABL1 fusion transcript. His cytogenetic analysis... 
CML | BCR/ABL | IMATINIB TREATMENT | CHRONIC MYELOID-LEUKEMIA | dasatinib | BCR-ABL FUSION | GENE | ONCOLOGY | BCR-ABL1 | ACUTE LYMPHOBLASTIC-LEUKEMIA | OUTCOMES | PCR | e13a3 | Translocation | BCR protein | Hematology | Transcription | Leukemia | Philadelphia chromosome | Polymerase chain reaction | Primers | Cytogenetics | Catalysis | Mutation | Chromosomes | Elderly | Geriatrics
Journal Article
International Journal of Hematology, ISSN 0925-5710, 7/2012, Volume 96, Issue 1, pp. 142 - 143
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, p. e0158392
Journal Article